Managing Global Clinical Trials and Promoting Diversity: Insights from a Clinical Operations Leader

Managing clinical trials on a global scale presents unique challenges, including varying regulatory environments, geopolitical situations and differing healthcare standards. One of the significant challenges in global clinical trials is ensuring diversity among trial participants.

Global Clinical Trials and Clinical Operations Leader — Dr. Karen Correa, PhD, BCMAS
Executive Biotech & Biopharma Leader

Promoting diversity in clinical trials is crucial for several reasons. It ensures that the data collected is representative of the broader population, which can improve the generalizability of the study results. Diverse clinical trials can also help identify varying responses to treatments among different demographic groups, ultimately leading to more effective and safer medical interventions for everyone.

In this insightful interview, Xtalks had the opportunity to speak with Dr. Karen Correa, PhD, BCMAS, an Executive Biotech & Biopharma Leader. Dr. Correa shared her expertise on managing clinical trials on a global scale, the unique challenges faced and the critical importance of promoting diversity within these trials.

This interview with Dr. Correa was conducted in 2024 when Dr. Correa was the current Vice President, Head Global Clinical Operations, Takeda.

XTALKS CLINICAL EDGE: Issue 3 — Interview with Dr. Karen Correa

Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials. This magazine immerses you in a world where industry leaders, patient advocates and top researchers converge to provide the most insightful perspectives on clinical trials.

Challenges of Managing Global Clinical Trials

Managing clinical trials on a global scale presents numerous challenges, which vary across different stages of a trial and therapeutic areas. Dr. Correa highlighted several key factors that must be considered:

Regulatory Environment: Different countries have varying regulatory requirements that need to be navigated.
Geopolitical Situations: Political climates can affect trial operations and logistics.
Supply Chain Challenges: Ensuring the smooth supply of trial materials can be complex.
Recruitment Challenges: These can differ significantly from one region to another.
Standard of Care: Varies across countries, influencing trial designs and outcomes.

Sponsors can address these challenges by integrating them into the clinical development plan from the outset and continuously adapting strategies as circumstances change. This proactive approach allows them to mitigate potential issues and ensure trial continuity and integrity.

The Impact of Diversity on Clinical Research Quality

Dr. Correa emphasized the positive impact of diversity on clinical research quality: “Diversity in clinical trials positively impacts the quality of a study. It provides insights on demographic regions to ensure that the data we utilize is generalizable within the population when approved.”

By including participants from various demographic backgrounds, researchers can identify differences in how diverse populations respond to treatments. This can lead to the development of more personalized and effective therapies, reducing health disparities and improving patient outcomes.

One of the major benefits of diversity in clinical trials is the ability to address health disparities among different populations. For instance, certain diseases and conditions may disproportionately affect specific racial or ethnic groups. By ensuring that these groups are adequately represented in clinical trials, researchers can better understand the disease mechanisms and develop targeted treatments.

Dr. Correa highlighted this point, stating, “Having this opportunity will help us address some of the health disparities that you might see among different populations by age, gender, sex and race.”

Moreover, diverse clinical trials can improve the overall reliability of study findings. Homogeneous study populations can lead to biased results that do not accurately reflect the effects of a treatment across different population groups. This can result in treatments that are less effective in underrepresented groups. Ensuring diversity helps mitigate this risk and enhances the credibility of the research.

The FDA and other regulatory bodies have recognized the importance of diversity in clinical trials and have issued guidelines to encourage broader participation. These guidelines emphasize the need for clinical trials to include diverse populations to ensure that the benefits and risks of treatments are well understood across all groups.

Diversity Initiatives to Implement in Clinical Operations

According to Dr. Correa, companies can implement several key initiatives to promote diversity in clinical trials:

Dedicated Diversity Teams: Teams focused on diversity are integral to the planning and execution of trials.
Diversity Action Plans: These are templates used to ensure every study incorporates a diversity plan from the start.
Community Partnerships: Engaging communities in the decision-making process ensures trials are more inclusive and representative.
Diverse Sites and Staff: Ensuring diversity among investigative sites and staff helps reach a broader patient population.
Addressing Barriers: Putting strategies in place to overcome barriers such as transportation, access, awareness and education.

These initiatives underscore commitment to not only meeting but exceeding diversity expectations in clinical research.

The Role of Regulatory Agencies in Promoting Diversity

Regulatory agencies play a crucial role in promoting diversity within clinical trials. According to Dr. Correa, these agencies provide essential guidance that set clear expectations for diversity in clinical research. These guidelines help organizations understand what is required to establish their own Diversity Action Plans, making it easier for them to develop and implement effective diversity strategies.

Beyond providing guidance, regulatory agencies also offer valuable feedback on diversity action plans submitted by organizations. This feedback helps companies refine their approaches, ensuring that their diversity initiatives are both practical and impactful. Dr. Correa emphasizes the importance of this feedback, noting that it helps organizations stay on track and make necessary adjustments to their strategies.

However, Dr. Correa believes that the most critical role of regulatory agencies is to hold organizations accountable for their diversity efforts. “I think it’s important for regulatory agencies to hold us accountable. I think that’s the most important piece. That’s the whole loop to the process,” she stated.

Accountability ensures that companies do not just create diversity plans but also actively implement and follow through on them. When organizations know they are being monitored and assessed, they are more likely to be proactive and intentional about their diversity initiatives.

The Future of Diversity in Clinical Trials

Looking ahead, Dr. Correa envisions a future where diversity in clinical trials is the norm. She expressed a desire for diversity to become second nature in trial design and execution, eliminating the need for it to be a separate consideration.

“I want it to be a norm. I don’t want it to be something that we have to think about.”

Dr. Correa’s insights highlight the critical importance of diversity in clinical trials and the multi-faceted approach required to manage global clinical operations effectively.